Recon: Roche to buy obesity drugmaker Carmot Therapeutics for $2.7B; Supreme Court hears oral arguments in Purdue bankruptcy case

• Lilly’s Jaypirca blazes leukemia trail with FDA nod, fast confirmatory trial filing (Fierce)
• Lawmakers want to know why it took the FDA so long to rule on decongestant phenylephrine (Fierce) (Endpoints)
• Clinical Trial Diversity Plans: Early Oncology Experience Shows More Work Needed, US FDA Says (Pink Sheet)
• US Supreme Court grapples with Purdue Pharma bankruptcy settlement case (Reuters)
• Explainer: How will the Supreme Court reshape US opioid epidemic relief? (Reuters)
• A well-meaning FDA policy is a threat to pediatric cancer treatment (STAT)
• Lilly's Jaypirca blazes leukemia trail with FDA nod, fast confirmatory trial filing (Fierce Pharma)

• Bigger Trials, More RWE Needed for Future Crisis Response, Say EU Regulators (Pink Sheet)
• EMA Requests More Data from GLP-1 Drugmakers in Suicidal Ideation, Self-Harm Probe (BioSpace)
• French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine (Pink Sheet)
• Premature Filings Add To EU Regulatory Resource Challenge (Pink Sheet)
• Novartis is building a new radioligand plant in China (STAT)
• Novartis unveils new brand identity after Sandoz spinoff (Endpoints)
• India finds quality issues with cough syrup linked to Cameroon deaths – sources (Reuters)
• WuXi Biologics’ stock slides by 24% as manufacturing business slows amid biotech downturn (Endpoints)
• South Africa's Aspen expands reach with $100M buy of Sandoz's Chinese business (Fierce Pharma)
• NASH market fattening up as wait for liver treatments drags on (Fierce Pharma)

• Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion (STAT) (Fierce)
• How sickle cell became the first disease treated by CRISPR (STAT)
• Up and down the ladder: The latest comings and goings (STAT)
• As Bayer confronts mounting Roundup losses, all eyes on Philadelphia trial (Reuters)
• Wet AMD biotech stock soars over 200% as lead asset matches Regeneron’s Eylea in PhII test (Endpoints)
• Seismic raises $121M to enter immunology space spotlighted by argenx, Immunovant and others (Endpoints)
• Abbisko signs $70M upfront deal with Merck KGaA for PhIII cancer drug (Endpoints)
• Orna Therapeutics trims staff in ‘defensive reduction’ despite large financing hauls (Endpoints)
• Exclusive: San Diego biotech raises $11.7M to use cells as targeted delivery vessels for genetic medicines (Endpoints)

• European Commission Launches Data Collection Initiative To Avoid Medtech Product Shortfalls (MedTech Insight)
• Member States Want Action Over High-Risk IVDs And Eudamed Medical Device Database (MedTech Insight)
• FDA Receives Thousands Of Opinions On Proposal To Regulate LDTs As Comment Period Comes To A Close (MedTech Insight)
• Johnson & Johnson bets heavy on AI-driven drug discovery (STAT)
• UCSF scientists aim to unravel autism with brain organoids and AI (Endpoints)
• AstraZeneca inks $247M deal with generative AI shop Absci to develop antibody drug for cancer (Endpoints)
• Nevro buys low back pain company Vyrsa for $40M (MedTech Dive)
• Resmed’s new C-suite focused on growing sleep apnea device demand: analysts (MedTech Dive)
• BD tells customers not to use Cardinal’s Monoject syringes with Alaris pumps (MedTech Dive)

• Big Weed today is a whole lot like Big Tobacco in the 1950s (STAT)
• STAT readers on burnt-out infectious disease doctors, 12-month prescriptions, and counting disabled Americans (STAT)
• CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program (FDA Law Blog)
• Veteran Big Pharma chief lashes out at Tucker Carlson, Elon Musk’s drug ad criticism on X (Fierce Pharma)